EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro small molecule screening to inform novel candidates for use in fluconazole combination therapy in vivo against Coccidioides

Heather L Mead iD, Michael Valentine, Holly Yin, George R Thompson Iii, Paul Keim iD, David M Engelthaler iD, Bridget M Barker iD

Microbiology Spectrum · 2024

DOI: 10.1128/spectrum.01008-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2024. Verfasst von Heather L Mead und 6 weiteren Autor:innen. Beteiligte Einrichtung: The Translational Genomics Research Institute North, Flagstaff, Arizona, USA. Hauptthemen laut MEDLINE: Fluconazole, Coccidioides, Coccidioidomycosis, Antifungal Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | National Institutes of Health (NIH).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Identifying improved treatments for severe and refractory coccidioidomycosis (Valley fever) is needed. This endemic fungal disease is common in North and South America, and cases have increased substantially over the last 30 years. The current standard of care, oral daily fluconazole, often fails to completely eradicate Coccidioides infection; however, the high cost of identifying new compounds effective in treating Valley fever is a barrier to improving treatment. Therefore, repurposing existing pharmaceutical agents in combination with fluconazole therapy is an attractive option. We screened the Library of Pharmacologically Active Compounds (LOPAC) small molecule library for compounds that inhibited fungal growth in vitro and determined IC 50 values for a subset of compounds. Based on these findings, we tested a small subset of these agents to validate the screen, as well as to test the performance of fluconazole in a combination therapy approach, as compared with fluconazole alone, in a murine model. We observed that combination therapy of tamoxifen:fluconazole and sertraline:fluconazole significantly reduced the burden of live fungus in the lung compared with fluconazole alone, and we observed reduced or nonexistent dissemination. These results suggest that tamoxifen and sertraline may be repurposed as adjunctive agents in the treatment of this important fungal disease. IMPORTANCE Developing new drugs, especially for regional orphan diseases, such as Valley Fever, is a slow and costly endeavor. However, there is a wealth of FDA-approved drugs available for repurposing, offering a more economical and expedited approach to improve treatment. Those existing compounds with antifungal properties can become novel therapies with relative ease: a considerable advantage for patients in need of alternative treatment. Despite the scope of remaining tasks, our comprehensive screening of potential candidates has revealed promising combinations for further exploration. This effort outlines a practical pipeline for Valley fever drug screening and identifies viable drug combinations that could impact patients more rapidly than single drug development pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FluconazoleCoccidioidesCoccidioidomycosisAntifungal AgentsDrug Therapy, CombinationAnimalsMiceSmall Molecule LibrariesHumansMicrobial Sensitivity TestsDisease Models, AnimalDrug RepositioningFemaleDrug Evaluation, Preclinical

Stichwörter der Autor:innen

CoccidioidesValley Feveradjunctive agentantifungal therapycoccidioidomycosisfungal infectionsertraline

Substanzen

FluconazoleAntifungal AgentsSmall Molecule Libraries

Autor:innen und Institutionen

  • The Translational Genomics Research Institute North, Flagstaff, Arizona, USA.
  • Beckman Research Institute of the City of Hope, Duarte, California, USA.
  • Department of Internal Medicine, Division of Infectious Diseases, University of California-Davis, Sacramento, California, USA.
  • Department of Medical Microbiology and Immunology, University of California-Davis, Sacramento, California, USA.
  • Department of Biological Sciences, The Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.

ORCID-Profile: Heather L Mead, Paul Keim, David M Engelthaler, Bridget M Barker

Förderung

  • NIAID NIH HHS
  • HHS | National Institutes of Health (NIH)

Zitieren

APA

Mead, H. L., Valentine, M., Yin, H., Thompson Iii, G. R., Keim, P., Engelthaler, D. M., & Barker, B. M. (2024). In vitro small molecule screening to inform novel candidates for use in fluconazole combination therapy in vivo against Coccidioides. Microbiology Spectrum. https://doi.org/10.1128/spectrum.01008-24

Vancouver

Mead HL, Valentine M, Yin H, Thompson Iii GR, Keim P, Engelthaler DM, et al. In vitro small molecule screening to inform novel candidates for use in fluconazole combination therapy in vivo against Coccidioides. Microbiology Spectrum. 2024. doi:10.1128/spectrum.01008-24

BibTeX
@article{Mead2024,
  author = {Mead, Heather L and Valentine, Michael and Yin, Holly and Thompson Iii, George R and Keim, Paul and Engelthaler, David M and Barker, Bridget M},
  title = {In vitro small molecule screening to inform novel candidates for use in fluconazole combination therapy in vivo against Coccidioides},
  journal = {Microbiology Spectrum},
  year = {2024},
  doi = {10.1128/spectrum.01008-24}
}
Kostenlos starten →